Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001197345 | SCV001368039 | uncertain significance | Iminoglycinuria | 2019-03-20 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PP3. |
Fulgent Genetics, |
RCV002484070 | SCV002786021 | uncertain significance | Hyperglycinuria; Neutral 1 amino acid transport defect; Iminoglycinuria | 2021-09-15 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003117840 | SCV003789174 | uncertain significance | not provided | 2022-03-28 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 490 of the SLC6A19 protein (p.Gly490Ser). This variant is present in population databases (rs775323445, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SLC6A19-related conditions. ClinVar contains an entry for this variant (Variation ID: 931106). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003293988 | SCV004002297 | uncertain significance | Inborn genetic diseases | 2023-06-02 | criteria provided, single submitter | clinical testing | The c.1468G>A (p.G490S) alteration is located in exon 10 (coding exon 10) of the SLC6A19 gene. This alteration results from a G to A substitution at nucleotide position 1468, causing the glycine (G) at amino acid position 490 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |